Zeria Pharmaceutical (4559) · FactFirst stated

Financing through borrowings related to the acquisition of rights to Entocort

First written in FY2016. . Latest entry: FY2016.

1entries

1years

0from disclosures

Share on X

How it moved

Same theme, other companies

Borrowing to Fund License Fee PrepaymentsA theme 4 companies write about · 0 as a headwind · 4 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2016First statedAnnual report
「Because Tillotts Pharma AG primarily financed the acquisition of the Entocort rights from AstraZeneca through borrowings, total short- and long-term borrowings increased by ¥21,482 million from the end of the previous consolidated fiscal year.」
The disclosure states that the acquisition was financed and borrowings increased as a result.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.